Where does Intercept Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Intercept Pharmaceuticals, Inc. ranks #6,798 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Intercept Pharmaceuticals, Inc. hold?

Intercept Pharmaceuticals, Inc. holds 49 US utility patents granted between 2015 and 2025, spanning 6 technology areas.

What is Intercept Pharmaceuticals, Inc.'s Innovation Score?

Intercept Pharmaceuticals, Inc. has an Innovation Score of 32.5 out of 100 (41st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Intercept Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Intercept Pharmaceuticals, Inc.'s recent grant velocity is +4% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Intercept Pharmaceuticals, Inc.'s patents?

Intercept Pharmaceuticals, Inc.'s patents average 13.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Intercept Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Intercept Pharmaceuticals, Inc.

Q: What technology areas does Intercept Pharmaceuticals, Inc. focus on?

Intercept Pharmaceuticals, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 42 patents. Grants appear in 6 CPC subclasses total.

USPTO PatentsView assignee record - 49 granted patents across 6 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Intercept ranks #6,798 of 49,997 tracked US assignees by granted-patent volume, with 49 patents across 6 technology areas.

#6,798
of 49,997 US assignees by volume: 41st percentile
by Innovation Score (32.5/100): 13.8
avg claims per patent: +4%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6798 · US Corporation #6,798 · 49 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-SMALL 49 grants
UPPER-Q #6,798/49,997
PHOTO-FINISH Imertech SAS
CPC-NARROW A61P · 6 areas
INNOV-THIN 32.5/100
CLAIMS-RICH 13.8 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +4% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Imertech SAS (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
GiMer Medical · near

33
ViiV Healthcare · near

33
Gebr Kemper + KG… · near

32
Gibson Brands · near

32
Intercept Pharmaceut… · this assignee

32
3D Lighting… · lowest

7

What this shows Intercept's Innovation Score is 32.5/100 (41st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Intercept's grants concentrate

Intercept Pharmaceuticals, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 85.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (11 grants) versus a trough of 1 in 2023. By volume, Intercept sits between Imertech SAS and Jasco Products Company LLC.

Intercept's three-year grant acceleration

From 2019–2021 to 2022–2024, Intercept Pharmaceuticals, Inc. moved from 23 to 7 grants (0.30x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Imertech SAS

49
Insmed Incorporat…

49
Institute for Mus…

49
Interactions

49
Inventus Power

49
Japan Agency FOR…

49
Jiangsu Universit…

49
Jasco Products

49
Intercept Pharmac… ◀

49

What this shows Intercept holds 49 patents at rank #6,799, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Intercept

By rank, the assignees closest to #6,799 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Intercept's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Intercept, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (32 here).

Gibson Brands, Inc. 32 Gebr. Kemper GmbH + Co. KG Metallwerke 32 GiMer Medical Company Limited 33 ViiV Healthcare Company 33

Intercept's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 41st percentile higher than 41% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Intercept Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	6.1%
2016	3	6.1%
2017	7	14.3%
2018	4	8.2%
2019	6	12.2%
2020	11	22.4%
2021	6	12.2%
2022	6	12.2%
2023	1	2.0%
2025partial year	2	4.1%

Which technologies does Intercept Pharmaceuticals, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 42

C07J - Steroids 39

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 29

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 7

C07C - Acyclic OR Carbocyclic Compounds 3

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

Top 6 of 6 technology areas

Where it ranks

Overall rank by patents

#6,798

of 49,997 tracked assignees

Innovation Score

32.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Intercept Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Intercept Pharmaceuticals, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #6,798 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Intercept Pharmaceuticals, Inc. against Imertech SAS, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.